Methods of treating disease with random copolymers

Details Methods of treating disease with random copolymers Methods of treating disease with random copolymers

2005-11-17

2010-02-02

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

C424S078370, C514S002600

Reexamination Certificate

active

07655221

ABSTRACT:
The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.

REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz et al.
patent: 2001/0007758 (2001-07-01), Weiner et al.
patent: 2002/0055466 (2002-05-01), Aharoni et al.
patent: 2002/0183385 (2002-12-01), Ellison et al.
patent: 2003/0004099 (2003-01-01), Eisenbach-schwartz et al.
patent: 2004/0038887 (2004-02-01), Strominger et al.
patent: WO 92/02543 (1992-02-01), None
patent: WO 00/05249 (2000-02-01), None
patent: WO 00/05250 (2000-02-01), None
patent: WO 00/18794 (2000-04-01), None
patent: WO 00/20010 (2000-04-01), None
patent: WO 00/27417 (2000-05-01), None
patent: WO 03/000277 (2003-01-01), None
patent: WO 03/029276 (2003-04-01), None
patent: WO 03/047500 (2003-06-01), None
patent: WO 03/074546 (2003-09-01), None
patent: WO 2004/064717 (2004-08-01), None
patent: WO-2005/112972 (2005-12-01), None
patent: WO-2005/120542 (2005-12-01), None
Merriam Webster's Collegiate Dictionary, Tenth Edition, 1996, p. 36.
KMLE Medical Dictionary—Online medical dictionary, terminology, abbreviations, drugs. 2006-2007, pp. 1-8, http://www.kmle.com.
George C. Tsokos, M.D., B Cells, Be Gone—B-Cell Depletion in the Treatment of Rheumatoid Arthritis, New England Journal of Medicine, vol. 350, No. 25, Jun. 17, 2005, pp. 2546-2548.
Bert A. 't hart, et al., Evaluating the validity of animal models for research into therapies for immune-based disorders, DDT, Jun. 12, 2004, vol. 9, No. 12, pp. 517-524.
Herman Waldmann, Clinical Use of Campath -1H, Transplantation Reviews, Oct. 2003, vol. 17, No. 4, pp. S5-S7.
Michael H. Barnett and John W. Rinease, Relapsing and Remitting Multiple Sclerosis: Pathology of the Newly Forming Lesion, Ann. Neurol., 2004, vol. 55, pp. 458-468.
Abhijit Chaudhuri and Peter O. Behan, Multiple Sclerosis is Not an Autoimmune Disease, Arch Neurol., Oct. 2004, vol. 61, pp. 1610-1612.
Daniel Altmann, Evaluating the Evidence for Multiple Sclerosis an Autoimmune Disease and In Reply Abhijit Chaudhuri and Peter O. Behan, , Arch Neurol., Apr. 2005, vol. 62, pp. 688-690.
Fridkis-Hareli et al., “Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis”, The Journal of Clinical Investigation, Jun. 2002, vol. 109, No. 12, pp. 1635-1643.
Suhayl Dhib-Jalbut, “Glatiramer acetae (cCpaxone® ) therapy for multiple sclerosis”, Pharmacology & Therapeutics, 98 (2003) pp. 245-255.
Illes Zsolt et al., “Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells”, Proc. Natl. Acad. of Sciences; vol. 101, No. 32, (2004) (Abstract).
Farina et al., “Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action”, http:/
eurology.thelancet.com, vol. 4, 567-575, Sep. 2005.
http://eanatomy.cc/4.htm, Section 4, The Acquired Immune Respose, 1-71, May 9, 2005.
Kersten et al., “Antigen delivery systems”, Expert Rev. Vaccines 3(4), 453-462, 2004.
Flechter et al., “Copolymer 1 (Glatiiramer Acetate) in Relapsing Forms of Multiple Sclerosis:Open Multicenter Study of Alterntae-Day Administration”, Clinical Neuropharmacology, vol. 25, No. 1, Nov. 15, 2002.
Karandikar et al., “Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patientes with multiple sclerosis”, The Journal of Clinical Investigation, vol. 109, No. 5, 641-649, Mar. 2002.
Fridkis-Hareli et al., “Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells—specificity and promiscuity”, Proc. Natl. Acad. Sci. USA, vol. 91, 4872-4876, May 1994.
Jacchieri et al., “Proving the Influence of Sequence-Dependent Interactions upon α-Helix Stability in Alanine-Based Linear Peptides”, Biopolymers, vol. 33, No. 6, 971-984, 1993.
Fridkis-Hareli et al., “Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis”, The Journal of Clinical Investigation, vol. 109, No. 12, 1635-1643, Jun. 2002.
International Search Report dated Jul. 20, 2007 from corresponding application PCT/US2006/044864.
International Search Report dated Jul. 6, 2007 from corresponding application No. PCT/US2006/044699.
Li, Q. et al., “Glatiramer acetate blocks the activation of THP-1 cells by interferon-γ”, European Journal of Pharmacology, vol. 342, 1998, 303-310.
Melton, L. et al., “Designed polyanionic coiled-coil proteins: acceleration of heparin cofactor II inhibition of thrombin”, Int. J. Peptide Protein Res., 45, 1995, 44-52.
Wagner, D. et al., “Deuterium exchange of α-helices and β-sheets as monitored by electrospray ionization mass spectrometry”, Protein Science, 3, 1994, 1305-1314.
European Search Report dated Feb. 27, 2008 from European Application No. 05724381.8.
Saoudi et al., Is pathogenic humoral autoimmunity a Th1 response?, Immunology Today, vol. 21, 6, 2000, pp. 306-307.

Affiliated with

Also associated with

Rating

Methods of treating disease with random copolymers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating disease with random copolymers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating disease with random copolymers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4225411